Lavipharm

Lavipharm P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Lavipharm (LAVI.AT) as of Oct 16, 2026 is 116.60. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -47.70 — a change of -344.46% (higher).

P/FCF

116.60

YoY

-344.46%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Lavipharm is 2025 116.60 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Lavipharm was 2024 -47.70 . It decreases by -344.46% higher compared to the previous year.

The Lavipharm P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
619.97 EUR
Jan 1, 2019
500.40 EUR
Jan 1, 2020
173.72 EUR
Jan 1, 2021
125.49 EUR
Jan 1, 2022
-7.40 EUR
Jan 1, 2023
-63.40 EUR
Jan 1, 2024
-47.70 EUR
Jan 1, 2025
116.60 EUR
The Lavipharm P/FCF history
YEARP/FCFYoY
116.60-344.46%
-47.70-24.76%
-63.40+757.10%
-7.40-105.89%
125.49-27.76%
173.72-65.28%
500.40-19.29%
619.97+202.34%
205.06-56.27%
468.94+8.64%
431.63+90.52%
226.55—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Lavipharm Stock analysis

What does Lavipharm do? Lavipharm SA is a pharmaceutical company based in Athens, Greece, operating within the Health Care sector. The company, listed on the Vienna Stock Exchange under ticker LAVI.AT, has an ISIN code of GRS246003008. Lavipharm SA was founded through an IPO on November 8, 1995, and currently employs 184 full-time staff. The company engages in the manufacture and import of pharmaceuticals and veterinary products. Its product portfolio includes pharmaceuticals for anti-inflammatory, asthma, neurological, antiseptic, analgesic, dermatological, and gastrointestinal treatments. Additionally, Lavipharm SA offers cosmetic products under the brand names Castalia Soins Dermocosmetiques and Laviderm Active Technology, targeting skin, face, body, scalp, and hair care. The company also distributes over-the-counter (OTC) products such as cold and flu remedies, oral care items, dermatological products, condoms, antiseptics, analgesics, laxatives, and gynecological products. Lavipharm SA is the parent company of the Lavipharm Group of Companies. In January 2014, Robertet SA, alongside CODIF, acquired HITEX, a company specializing in carbon dioxide extraction subcontracting, from Lavipharm SA. The company maintains a website at https://www.lavipharm.com/. Lavipharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lavipharm stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Lavipharm is 116.60 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Lavipharm changed from -47.70 to 116.60, representing a -344.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Lavipharm since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Lavipharm with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Lavipharm

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Lavipharm